<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00438880</url>
  </required_header>
  <id_info>
    <org_study_id>LS0382</org_study_id>
    <secondary_id>NCI-2009-01275</secondary_id>
    <secondary_id>LS0382</secondary_id>
    <secondary_id>P30CA015083</secondary_id>
    <nct_id>NCT00438880</nct_id>
  </id_info>
  <brief_title>Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma</brief_title>
  <official_title>A Phase I/II Trial of CpG 7909, Rituximab Immunotherapy, and Y-90 Zevalin Radioimmunotherapy for Patients With Previously Treated CD20+ Non-Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapies, such as agatolimod sodium, may stimulate the immune system
      in different ways and stop cancer cells from growing. Monoclonal antibodies, such as
      rituximab, can block cancer growth in different ways. Some block the ability of cancer cells
      to grow and spread. Others find cancer cells and help kill them or carry cancer-killing
      substances to them. Radiolabeled monoclonal antibodies, such as yttrium Y 90 ibritumomab
      tiuxetan, can find cancer cells and carry cancer-killing substances to them without harming
      normal cells. Giving agatolimod sodium together with rituximab and yttrium Y 90 ibritumomab
      tiuxetan may kill more cancer cells.

      PURPOSE: This phase I/II trial is studying the side effects and best dose of agatolimod
      sodium when given together with rituximab and yttrium Y 90 ibritumomab tiuxetan and to see
      how well it works in treating patients with recurrent or refractory non-Hodgkin lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the maximum tolerated dose of CpG 7909 that can be delivered in four doses
      (days 6, 13, 20, 27) for patients with relapsed CD20+ non-Hodgkin's lymphoma. (Phase I) II.
      To assess the toxicity of CpG 7909 when combined with rituximab and Y-90 Zevalin in patients
      with lymphoma. (Phase I) III. To assess the overall response rate (CR + PR) of this regimen
      in relapsed diffuse large B cell lymphoma. (Phase II) IV. To assess the toxicity of the
      treatment regimen in patients with relapsed diffuse large B cell lymphoma. (Phase II) V. To
      assess the time to progression and duration of response in patients with relapsed diffuse
      large B cell lymphoma. (Phase II)

      SECONDARY OBJECTIVES:

      I. To report the response rate (complete remission + complete remission unconfirmed + partial
      remission) in this patient population after CpG 7909, rituximab, and Y-90 Zevalin. (Phase I)
      II. To compare the biodistribution of In-111 Zevalin radioimmunoconjugate scans before and
      after CpG 7909. (Phase I) III. To determine the HAMA/HACA rate in patients treated with this
      regimen. (Phase I) IV. To determine if CpG 7909 when given in the context of rituximab and
      Y-90 Zevalin can stimulate immune effector cells in the blood and tumor tissue. (Phase I)

      OUTLINE:

      This is a dose escalation study of agatolimod sodium followed by a phase II study.

      PHASE I (patients with relapsed, refractory, or residual CD20+ non-Hodgkin lymphoma [closed
      to accrual as of 10/29/07]): Patients receive rituximab IV on days 1, 8 and 15, agatolimod
      sodium IV over 2 hours on days 6, 13, 20, and 27, and yttrium Y 90 ibritumomab tiuxetan* IV
      over 10 minutes on day 15 in the absence of disease progression and unacceptable toxicity.

      *NOTE: Patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on days 1 and
      8. Patients undergo whole-body gamma camera imaging, single-photon emission computed
      tomography/CT scans, and blood sampling after each dose of indium In 111 ibritumomab tiuxetan
      to determine biodistribution. If biodistribution is acceptable, patients receive yttrium Y 90
      ibritumomab tiuxetan.

      PHASE II (patients with relapsed, refractory, or residual diffuse large B-cell lymphoma):
      Patients receive agatolimod sodium at the MTD as determined in phase I. Patients receive
      rituximab and yttrium Y 90 ibritumomab tiuxetan as in phase I.

      *NOTE: Patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 8.
      Patients undergo whole-body gamma camera imaging and blood sampling after each dose of indium
      In 111 ibritumomab tiuxetan to determine biodistribution.

      After completion of study treatment, patients are followed periodically for up to 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose of CpG 7909 as Determined Using the Number of Participants With a DLT at Each Dose Level</measure>
    <time_frame>at least 10 weeks post treatment up to 3 months.</time_frame>
    <description>Participants will be treated in cohorts of 6 patients at each dose level of CpG 7909 (0.08 mg/kg, 0.16 mg/kg, 0.32 mg/kg, 0.48 mg/kg) and observed for at least 10 weeks post treatment. If at most one of the 6 patients experiences a dose limiting toxicity (DLT), a new cohort of 6 patients will be treated at the next higher dose level. A DLT for this study is defined as patients with one of the following:
Absolute neutrophil counts or platelet counts below 10*10^9/L for 14 days
Absolute neutrophil counts greater than 0.5 or less than 1*10^9/L
Platelet counts greater than 10 or less than 50*10^9/L for 28 days.
Any grade 3 non-hematologic toxicity not explainable by another obvious cause as assessed using the Common Terminology Criteria for Adverse Events (CTCAE) v3.0.
We are reporting the number of DLTs at each of the dose levels. The maximum tolerated dose will be 0.48 mg/kg or the largest dose level where 1 or fewer participants reports a dose limiting toxicity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor Response</measure>
    <time_frame>Evaluations occur every three months up to a year</time_frame>
    <description>Complete Response (CR):
No measurable or nonmeasurable disease.
No symptoms of Lymphoma.
Non-palpable spleen, if palpable at baseline.
Histologically negative bone marrow, if positive at baseline.
All nodes &lt;1.5 cm in transverse diameter.
Partial Response (PR):
greater than 50% decrease from baseline in the sum of the products of the longest perpendicular diameters of the six largest dominant lesions.
No new lesions
We are reporting the number of participants that attained a status of CR or PR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>Up to 1 year from treatment start date</time_frame>
    <description>The Progression-free survival (PFS) is defined as the time from registration to progression or death due to any cause. The distribution of PFS will be estimated using the method of Kaplan-Meier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Up to 1 year from treatment start date</time_frame>
    <description>Duration of response (DoR) will be calculated from the documentation of response until the date of progression in the subset of patients who respond.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Adult Non-Hodgkin Lymphoma</condition>
  <condition>Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue</condition>
  <condition>Nodal Marginal Zone Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Recurrent Grade 1 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 2 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 3 Follicular Lymphoma</condition>
  <condition>Recurrent Mantle Cell Lymphoma</condition>
  <condition>Recurrent Marginal Zone Lymphoma</condition>
  <condition>Recurrent Small Lymphocytic Lymphoma</condition>
  <condition>Splenic Marginal Zone Lymphoma</condition>
  <condition>Waldenstrom Macroglobulinemia</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Detailed Description</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Agatolimod Sodium</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>(3'-5')d(P-thio)(T-C-G-T-C-G-T-T-T-T-G-T-C-G-T-T-T-T-G-T-C-G-T-T) Tricosasodium Salt</other_name>
    <other_name>CpG 7909</other_name>
    <other_name>PF-3512676</other_name>
    <other_name>ProMune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Indium In-111 Ibritumomab Tiuxetan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>IDEC In2B8</other_name>
    <other_name>IDEC-In2B8</other_name>
    <other_name>In 111 Ibritumomab Tiuxetan</other_name>
    <other_name>In 111 Zevalin</other_name>
    <other_name>indium In 111 ibritumomab tiuxetan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative study</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radionuclide Imaging</intervention_name>
    <description>Undergo imaging scans</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>nuclear medicine scan</other_name>
    <other_name>radioimaging</other_name>
    <other_name>Radionuclide Scanning</other_name>
    <other_name>Scan</other_name>
    <other_name>SCINTIGRAPHY</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>BI 695500</other_name>
    <other_name>C2B8 Monoclonal Antibody</other_name>
    <other_name>Chimeric Anti-CD20 Antibody</other_name>
    <other_name>IDEC-102</other_name>
    <other_name>IDEC-C2B8</other_name>
    <other_name>IDEC-C2B8 Monoclonal Antibody</other_name>
    <other_name>MabThera</other_name>
    <other_name>Monoclonal Antibody IDEC-C2B8</other_name>
    <other_name>PF-05280586</other_name>
    <other_name>Rituxan</other_name>
    <other_name>Rituximab Biosimilar BI 695500</other_name>
    <other_name>Rituximab Biosimilar PF-05280586</other_name>
    <other_name>Rituximab Biosimilar RTXM83</other_name>
    <other_name>RTXM83</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Single Photon Emission Computed Tomography</intervention_name>
    <description>Undergo imaging scans</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>Medical Imaging, Single Photon Emission Computed Tomography</other_name>
    <other_name>Single Photon Emission Tomography</other_name>
    <other_name>single-photon emission computed tomography</other_name>
    <other_name>SPECT</other_name>
    <other_name>SPECT imaging</other_name>
    <other_name>SPECT SCAN</other_name>
    <other_name>SPET</other_name>
    <other_name>tomography, emission computed, single photon</other_name>
    <other_name>Tomography, Emission-Computed, Single-Photon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Yttrium Y-90 Ibritumomab Tiuxetan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>IDEC-Y2B8</other_name>
    <other_name>IDEC-Y2B8 monoclonal antibody</other_name>
    <other_name>Y 90 Ibritumomab Tiuxetan</other_name>
    <other_name>Y 90 Zevalin</other_name>
    <other_name>Yttrium Y 90 Ibritumomab Tiuxetan</other_name>
    <other_name>yttrium Y90 ibritumomab tiuxetan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The following histologic types by REAL classification and International Working
             Formulation (IWF) when applicable (NOTE: Closed to accrual as of 10/29/07): Small
             lymphocytic lymphoma; Lymphoplasmacytoid lymphoma; Follicular center lymphoma,
             follicular grades 1, 2, and 3; Extranodal marginal zone B cell lymphoma of MALT type;
             Nodal marginal zone B cell lymphoma

          -  The following histologic types by REAL classification and International Working
             Formulation (IWF) when applicable: Diffuse large cell; Transformed lymphoma

          -  Less than 25% bone marrow involvement of cellular marrow with lymphoma as determined
             by bilateral bone marrow aspirate and biopsy (the percent involvement should be
             estimated by the hematopathologist using all of the biopsy material)

          -  There is no limit on the number of prior therapies (patients who have previously
             received rituximab are eligible)

          -  Bi-dimensionally measurable disease: The patients must have &gt;= 1 lesion that has a
             single diameter of &gt;= 2 cm

          -  Absolute neutrophil count &gt;= 1500/mm^3

          -  Platelet count &gt;= 150,000

          -  Total lymphocyte count &lt; 5000/mm^3 only for patients with small lymphocytic lymphoma

          -  HGB &gt;= 8

          -  Biopsy-proven relapsed, refractory, or residual CD20+ non-Hodgkin's lymphomas;
             previous biopsies =&lt;6 months prior to treatment on this protocol will be acceptable as
             long as there has not been intervening therapy; if the patient has received therapy
             for NHL between the time of the last biopsy and this protocol, then a re-biopsy is
             necessary

          -  ECOG performance status (PS) 0, 1, or 2

          -  Expected survival &gt;= 3 months

          -  Willingness to provide all biologic specimens as required by the protocol

          -  Total bilirubin =&lt; 2 x ULN mg/dL (if abnormal, direct bilirubin =&lt; 1.5 x ULN)

        Exclusion Criteria:

          -  Prior myeloablative therapies with autologous or allogeneic bone marrow
             transplantation or peripheral blood stem cell support

          -  Prior radioimmunotherapy including Y-90 Zevalin or 131-Iodine anti-B1 antibody or
             Lym-1

          -  Presence of CNS lymphoma

          -  Serious non-malignant disease such as active infection or other condition which in the
             opinion of the investigator would compromise other protocol objectives

          -  Major surgery other than diagnostic surgery =&lt; 4 weeks prior to registration

          -  Another active primary malignancy

          -  Known HAMA/HACA (Human anti-mouse or anti-chimeric antibodies)

          -  Myelodysplastic syndrome or marrow chromosomal changes suggesting myelodysplasia

          -  Pregnant women

          -  Nursing women

          -  Men or women of childbearing potential who are unwilling to employ adequate
             contraception (condoms, diaphragm, birth control pills, injections, intrauterine
             device [IUD], surgical sterilization, abstinence, etc.)

          -  Failed stem cell collection

          -  Marrow cellularity =&lt; 15% (as determined on all bone marrow samples)

          -  Known to have lymphoma related to HIV or AIDS (these patients are excluded because it
             is unknown what effects prolonged B-cell depletion will have on these patient's immune
             system)

          -  G-CSF or GM-CSF therapy =&lt; 1 week prior to study registration (pegylated filgrastim =&lt;
             3 weeks)

          -  Myelosuppressive chemotherapy =&lt; 3 weeks prior to study registration (=&lt; 6 weeks if
             rituximab, nitrosourea, or Mitomycin C)

          -  Skin rash (such as Stevens-Johnson's syndrome or toxic epidermal necrolysis) with
             prior rituximab therapy should not be entered on this study because of the risk of
             reoccurrence of that skin toxicity

          -  Abnormal renal function (serum creatinine &gt; 2 mg/dL)

          -  Pre-existent clinical autoimmune or antibody mediated diseases, including systemic
             lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sjogren's syndrome, and
             autoimmune thrombocytopenia (patients that have no clinical symptoms of these
             diseases, but merely have previously detected antibodies are eligible)

          -  Received prior external beam radiation therapy to &gt; 25% of active bone marrow

          -  Corticosteroid therapy at the time the patient enters the protocol; patients using
             prednisone or its equivalent for adrenal failure or using &lt; 20mg of prednisone/day for
             other benign causes are accepted
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Witzig</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Iowa/Holden Comprehensive Cancer Center</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2007</study_first_submitted>
  <study_first_submitted_qc>February 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2007</study_first_posted>
  <results_first_submitted>May 20, 2014</results_first_submitted>
  <results_first_submitted_qc>August 20, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 1, 2014</results_first_posted>
  <last_update_submitted>January 4, 2016</last_update_submitted>
  <last_update_submitted_qc>January 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Phase I of this study opened 10/20/2004 and accrued 30 patients before closing 10/29/2007. Eight patients were accrued to the Phase II portion at the maximum tolerated dose established in Phase I.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Phase I</title>
          <description>Phase I patients will receive the following treatment:
250 mg/m^2 Rituximab IV on days 1, 8, and 15 of a 27 day cycle
5 mCi (Indium-111), 1.6 mg Ibritumomab IV on day 1
10 mCi (Indium-111), 1.6 mg Ibritumomab IV on day 8
CpG 7909 (Agatolimod Sodium) doses will be assigned in groups of 6 patients. Dose levels will escalate in each group until maximum tolerability is attained (starting at 0.08 mg/kg and sequentially escalating to 0.16 mg/kg, 0.32 mg/kg, 0.48 mg/kg). Doses will be taken day 6, 13, 20, and 27 of a 27 day cycle.
0.4 mCi/kg Yttrium-90 Zevalin IV on day 15</description>
        </group>
        <group group_id="P2">
          <title>Phase II</title>
          <description>Phase II patients will receive the following treatment:
250 mg/m^2 Rituximab IV on days 1, 8, and 15 of a 27 day cycle
5 mCi (Indium-111), 1.6 mg Ibritumomab IV on day 8
0.48 mg/kg CpG 7909 (Agatolimod Sodium) doses will be taken day 6, 13, 20, and 27 of a 27 day cycle.
0.4 mCi/kg Yttrium-90 Zevalin IV on day 15</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants accrued to this study were analyzed for baseline characteristics</population>
      <group_list>
        <group group_id="B1">
          <title>Phase I</title>
          <description>Phase I patients will receive the following treatment:
250 mg/m^2 Rituximab IV on days 1, 8, and 15 of a 27 day cycle
5 mCi (Indium-111), 1.6 mg Ibritumomab IV on day 1
10 mCi (Indium-111), 1.6 mg Ibritumomab IV on day 8
CpG 7909 (Agatolimod Sodium) doses will be assigned in groups of 6 patients. Dose levels will escalate in each group until maximum tolerability is attained (starting at 0.08 mg/kg and sequentially escalating to 0.16 mg/kg, 0.32 mg/kg, 0.48 mg/kg). Doses will be taken day 6, 13, 20, and 27 of a 27 day cycle.
0.4 mCi/kg Yttrium-90 Zevalin IV on day 15</description>
        </group>
        <group group_id="B2">
          <title>Phase II</title>
          <description>Phase II patients will receive the following treatment:
250 mg/m^2 Rituximab IV on days 1, 8, and 15 of a 27 day cycle
5 mCi (Indium-111), 1.6 mg Ibritumomab IV on day 8
0.48 mg/kg CpG 7909 (Agatolimod Sodium) doses will be taken day 6, 13, 20, and 27 of a 27 day cycle.
0.4 mCi/kg Yttrium-90 Zevalin IV on day 15</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.5" lower_limit="36" upper_limit="80"/>
                    <measurement group_id="B2" value="68.5" lower_limit="42" upper_limit="83"/>
                    <measurement group_id="B3" value="62.5" lower_limit="36" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose of CpG 7909 as Determined Using the Number of Participants With a DLT at Each Dose Level</title>
        <description>Participants will be treated in cohorts of 6 patients at each dose level of CpG 7909 (0.08 mg/kg, 0.16 mg/kg, 0.32 mg/kg, 0.48 mg/kg) and observed for at least 10 weeks post treatment. If at most one of the 6 patients experiences a dose limiting toxicity (DLT), a new cohort of 6 patients will be treated at the next higher dose level. A DLT for this study is defined as patients with one of the following:
Absolute neutrophil counts or platelet counts below 10*10^9/L for 14 days
Absolute neutrophil counts greater than 0.5 or less than 1*10^9/L
Platelet counts greater than 10 or less than 50*10^9/L for 28 days.
Any grade 3 non-hematologic toxicity not explainable by another obvious cause as assessed using the Common Terminology Criteria for Adverse Events (CTCAE) v3.0.
We are reporting the number of DLTs at each of the dose levels. The maximum tolerated dose will be 0.48 mg/kg or the largest dose level where 1 or fewer participants reports a dose limiting toxicity.</description>
        <time_frame>at least 10 weeks post treatment up to 3 months.</time_frame>
        <population>Only participants accrued to the Phase I portion of this study were used to determine the maximum tolerated dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I</title>
            <description>Phase I patients will receive the following treatment:
250 mg/m^2 Rituximab IV on days 1, 8, and 15 of a 27 day cycle
5 mCi (Indium-111), 1.6 mg Ibritumomab IV on day 1
10 mCi (Indium-111), 1.6 mg Ibritumomab IV on day 8
CpG 7909 (Agatolimod Sodium) doses will be assigned in groups of 6 patients. Dose levels will escalate in each group until maximum tolerability is attained (starting at 0.08 mg/kg and sequentially escalating to 0.16 mg/kg, 0.32 mg/kg, 0.48 mg/kg). Doses will be taken day 6, 13, 20, and 27 of a 27 day cycle.
0.4 mCi/kg Yttrium-90 Zevalin IV on day 15</description>
          </group>
          <group group_id="O2">
            <title>Phase II</title>
            <description>Phase II patients will receive the following treatment:
250 mg/m^2 Rituximab IV on days 1, 8, and 15 of a 27 day cycle
5 mCi (Indium-111), 1.6 mg Ibritumomab IV on day 8
0.48 mg/kg CpG 7909 (Agatolimod Sodium) doses will be taken day 6, 13, 20, and 27 of a 27 day cycle.
0.4 mCi/kg Yttrium-90 Zevalin IV on day 15</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose of CpG 7909 as Determined Using the Number of Participants With a DLT at Each Dose Level</title>
          <description>Participants will be treated in cohorts of 6 patients at each dose level of CpG 7909 (0.08 mg/kg, 0.16 mg/kg, 0.32 mg/kg, 0.48 mg/kg) and observed for at least 10 weeks post treatment. If at most one of the 6 patients experiences a dose limiting toxicity (DLT), a new cohort of 6 patients will be treated at the next higher dose level. A DLT for this study is defined as patients with one of the following:
Absolute neutrophil counts or platelet counts below 10*10^9/L for 14 days
Absolute neutrophil counts greater than 0.5 or less than 1*10^9/L
Platelet counts greater than 10 or less than 50*10^9/L for 28 days.
Any grade 3 non-hematologic toxicity not explainable by another obvious cause as assessed using the Common Terminology Criteria for Adverse Events (CTCAE) v3.0.
We are reporting the number of DLTs at each of the dose levels. The maximum tolerated dose will be 0.48 mg/kg or the largest dose level where 1 or fewer participants reports a dose limiting toxicity.</description>
          <population>Only participants accrued to the Phase I portion of this study were used to determine the maximum tolerated dose.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dose Level 1: (.08 mg/kg), n=6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose Level 2: (.16 mg/kg), n=6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose Level 3: (.32 mg/kg), n=6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose Level 4: (.48 mg/kg), n=12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tumor Response</title>
        <description>Complete Response (CR):
No measurable or nonmeasurable disease.
No symptoms of Lymphoma.
Non-palpable spleen, if palpable at baseline.
Histologically negative bone marrow, if positive at baseline.
All nodes &lt;1.5 cm in transverse diameter.
Partial Response (PR):
greater than 50% decrease from baseline in the sum of the products of the longest perpendicular diameters of the six largest dominant lesions.
No new lesions
We are reporting the number of participants that attained a status of CR or PR.</description>
        <time_frame>Evaluations occur every three months up to a year</time_frame>
        <population>Participants accrued to the Phase I portion of this study were not used to analyze the Phase II primary endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I</title>
            <description>Phase I patients will receive the following treatment:
250 mg/m^2 Rituximab IV on days 1, 8, and 15 of a 27 day cycle
5 mCi (Indium-111), 1.6 mg Ibritumomab IV on day 1
10 mCi (Indium-111), 1.6 mg Ibritumomab IV on day 8
CpG 7909 (Agatolimod Sodium) doses will be assigned in groups of 6 patients. Dose levels will escalate in each group until maximum tolerability is attained (starting at 0.08 mg/kg and sequentially escalating to 0.16 mg/kg, 0.32 mg/kg, 0.48 mg/kg). Doses will be taken day 6, 13, 20, and 27 of a 27 day cycle.
0.4 mCi/kg Yttrium-90 Zevalin IV on day 15</description>
          </group>
          <group group_id="O2">
            <title>Phase II</title>
            <description>Phase II patients will receive the following treatment:
250 mg/m^2 Rituximab IV on days 1, 8, and 15 of a 27 day cycle
5 mCi (Indium-111), 1.6 mg Ibritumomab IV on day 8
0.48 mg/kg CpG 7909 (Agatolimod Sodium) doses will be taken day 6, 13, 20, and 27 of a 27 day cycle.
0.4 mCi/kg Yttrium-90 Zevalin IV on day 15</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Response</title>
          <description>Complete Response (CR):
No measurable or nonmeasurable disease.
No symptoms of Lymphoma.
Non-palpable spleen, if palpable at baseline.
Histologically negative bone marrow, if positive at baseline.
All nodes &lt;1.5 cm in transverse diameter.
Partial Response (PR):
greater than 50% decrease from baseline in the sum of the products of the longest perpendicular diameters of the six largest dominant lesions.
No new lesions
We are reporting the number of participants that attained a status of CR or PR.</description>
          <population>Participants accrued to the Phase I portion of this study were not used to analyze the Phase II primary endpoint.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response (CR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response (PR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <description>The Progression-free survival (PFS) is defined as the time from registration to progression or death due to any cause. The distribution of PFS will be estimated using the method of Kaplan-Meier.</description>
        <time_frame>Up to 1 year from treatment start date</time_frame>
        <population>Only participants accrued to the Phase II portion of the study were evaluated for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I</title>
            <description>Phase I patients will receive the following treatment:
250 mg/m^2 Rituximab IV on days 1, 8, and 15 of a 27 day cycle
5 mCi (Indium-111), 1.6 mg Ibritumomab IV on day 1
10 mCi (Indium-111), 1.6 mg Ibritumomab IV on day 8
CpG 7909 (Agatolimod Sodium) doses will be assigned in groups of 6 patients. Dose levels will escalate in each group until maximum tolerability is attained (starting at 0.08 mg/kg and sequentially escalating to 0.16 mg/kg, 0.32 mg/kg, 0.48 mg/kg). Doses will be taken day 6, 13, 20, and 27 of a 27 day cycle.
0.4 mCi/kg Yttrium-90 Zevalin IV on day 15</description>
          </group>
          <group group_id="O2">
            <title>Phase II</title>
            <description>Phase II patients will receive the following treatment:
250 mg/m^2 Rituximab IV on days 1, 8, and 15 of a 27 day cycle
5 mCi (Indium-111), 1.6 mg Ibritumomab IV on day 8
0.48 mg/kg CpG 7909 (Agatolimod Sodium) doses will be taken day 6, 13, 20, and 27 of a 27 day cycle.
0.4 mCi/kg Yttrium-90 Zevalin IV on day 15</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>The Progression-free survival (PFS) is defined as the time from registration to progression or death due to any cause. The distribution of PFS will be estimated using the method of Kaplan-Meier.</description>
          <population>Only participants accrued to the Phase II portion of the study were evaluated for this endpoint.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1.57" lower_limit="1.22" upper_limit="3.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response</title>
        <description>Duration of response (DoR) will be calculated from the documentation of response until the date of progression in the subset of patients who respond.</description>
        <time_frame>Up to 1 year from treatment start date</time_frame>
        <population>The duration of response was not analyzed due to a lack of more than one response.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I</title>
            <description>Phase I patients will receive the following treatment:
250 mg/m^2 Rituximab IV on days 1, 8, and 15 of a 27 day cycle
5 mCi (Indium-111), 1.6 mg Ibritumomab IV on day 1
10 mCi (Indium-111), 1.6 mg Ibritumomab IV on day 8
CpG 7909 (Agatolimod Sodium) doses will be assigned in groups of 6 patients. Dose levels will escalate in each group until maximum tolerability is attained (starting at 0.08 mg/kg and sequentially escalating to 0.16 mg/kg, 0.32 mg/kg, 0.48 mg/kg). Doses will be taken day 6, 13, 20, and 27 of a 27 day cycle.
0.4 mCi/kg Yttrium-90 Zevalin IV on day 15</description>
          </group>
          <group group_id="O2">
            <title>Phase II</title>
            <description>Phase II patients will receive the following treatment:
250 mg/m^2 Rituximab IV on days 1, 8, and 15 of a 27 day cycle
5 mCi (Indium-111), 1.6 mg Ibritumomab IV on day 8
0.48 mg/kg CpG 7909 (Agatolimod Sodium) doses will be taken day 6, 13, 20, and 27 of a 27 day cycle.
0.4 mCi/kg Yttrium-90 Zevalin IV on day 15</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response</title>
          <description>Duration of response (DoR) will be calculated from the documentation of response until the date of progression in the subset of patients who respond.</description>
          <population>The duration of response was not analyzed due to a lack of more than one response.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Phase I</title>
          <description>Phase I patients will receive the following treatment:
250 mg/m^2 Rituximab IV on days 1, 8, and 15 of a 27 day cycle
5 mCi (Indium-111), 1.6 mg Ibritumomab IV on day 1
10 mCi (Indium-111), 1.6 mg Ibritumomab IV on day 8
CpG 7909 (Agatolimod Sodium) doses will be assigned in groups of 6 patients. Dose levels will escalate in each group until maximum tolerability is attained (starting at 0.08 mg/kg and sequentially escalating to 0.16 mg/kg, 0.32 mg/kg, 0.48 mg/kg). Doses will be taken day 6, 13, 20, and 27 of a 27 day cycle.
0.4 mCi/kg Yttrium-90 Zevalin IV on day 15</description>
        </group>
        <group group_id="E2">
          <title>Phase II</title>
          <description>Phase II patients will receive the following treatment:
250 mg/m^2 Rituximab IV on days 1, 8, and 15 of a 27 day cycle
5 mCi (Indium-111), 1.6 mg Ibritumomab IV on day 8
0.48 mg/kg CpG 7909 (Agatolimod Sodium) doses will be taken day 6, 13, 20, and 27 of a 27 day cycle.
0.4 mCi/kg Yttrium-90 Zevalin IV on day 15</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 6</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Leukocyte count decreased</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="20" subjects_affected="12" subjects_at_risk="30"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumor pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 6</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin decreased</sub_title>
                <counts group_id="E1" events="40" subjects_affected="19" subjects_at_risk="30"/>
                <counts group_id="E2" events="15" subjects_affected="8" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Localized edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Leukocyte count decreased</sub_title>
                <counts group_id="E1" events="63" subjects_affected="26" subjects_at_risk="30"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="37" subjects_affected="23" subjects_at_risk="30"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="34" subjects_affected="26" subjects_at_risk="30"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurological disorder NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Rash desquamating</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Thomas E. Witzig, M.D.</name_or_title>
      <organization>Mayo Clinic Cancer Center</organization>
      <email>witzig.thomas@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

